MetLife Investment Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.92M | Sell |
34,770
-20
| -0.1% | -$1.11K | 0.01% | 1012 |
|
|
2025
Q1 | $1.68M | Sell |
34,790
-1,008
| -3% | -$48.7K | 0.01% | 1123 |
|
|
2024
Q4 | $1.38M | Buy |
35,798
+1,993
| +6% | +$76.9K | 0.01% | 1255 |
|
|
2024
Q3 | $1.52M | Hold |
33,805
| – | – | 0.01% | 1165 |
|
|
2024
Q2 | $1.17M | Buy |
33,805
+5,209
| +18% | +$180K | 0.01% | 1262 |
|
|
2024
Q1 | $827K | Hold |
28,596
| – | – | 0.01% | 1405 |
|
|
2023
Q4 | $656K | Hold |
28,596
| – | – | ﹤0.01% | 1528 |
|
|
2023
Q3 | $477K | Hold |
28,596
| – | – | ﹤0.01% | 1668 |
|
|
2023
Q2 | $790K | Buy |
28,596
+4,682
| +20% | +$129K | 0.01% | 1402 |
|
|
2023
Q1 | $550K | Hold |
23,914
| – | – | ﹤0.01% | 1582 |
|
|
2022
Q4 | $261K | Hold |
23,914
| – | – | ﹤0.01% | 2080 |
|
|
2022
Q3 | $202K | Hold |
23,914
| – | – | ﹤0.01% | 2298 |
|
|
2022
Q2 | $189K | Hold |
23,914
| – | – | ﹤0.01% | 2363 |
|
|
2022
Q1 | $566K | Buy |
23,914
+8,826
| +58% | +$209K | ﹤0.01% | 1696 |
|
|
2021
Q4 | $516K | Hold |
15,088
| – | – | ﹤0.01% | 1489 |
|
|
2021
Q3 | $267K | Hold |
15,088
| – | – | ﹤0.01% | 1900 |
|
|
2021
Q2 | $677K | Buy |
15,088
+1,564
| +12% | +$70.2K | 0.01% | 1396 |
|
|
2021
Q1 | $350K | Hold |
13,524
| – | – | ﹤0.01% | 1725 |
|
|
2020
Q4 | $273K | Hold |
13,524
| – | – | ﹤0.01% | 1819 |
|
|
2020
Q3 | $264K | Buy |
13,524
+2,728
| +25% | +$53.3K | ﹤0.01% | 1690 |
|
|
2020
Q2 | $191K | Buy |
+10,796
| New | +$191K | ﹤0.01% | 1938 |
|
|
2019
Q4 | – | Sell |
-9,114
| Closed | -$109K | – | 2319 |
|
|
2019
Q3 | $109K | Buy |
+9,114
| New | +$109K | ﹤0.01% | 2285 |
|